Shandong Cancer Hospital and Institute: Breast Neoplasms trials

The registry lists 23 Breast Neoplasms studies with Shandong Cancer Hospital and Institute as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 2 9Phase 3 3Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted TherapyRecruitingNCT07376174
• Identification of HER2-Positive Breast Cancer Molecular Characterization and SubtypesNot yet recruitingNCT07187752Not applicable
• Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast CancerNot yet recruitingNCT07093931Phase 4
• Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerRecruitingNCT06802757Phase 2
• Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative ChemotherapyNot yet recruitingNCT03684863Phase 2
• Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS CohortStatus unknownNCT05054777
• Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)Status unknownNCT04676997Phase 2
• Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain MetastasisStatus unknownNCT04639271Phase 2
• Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBCStatus unknownNCT04609540
• Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast CancerStatus unknownNCT04568941Not applicable
• Metabolomics Explores Biomarkers for Metastatic Breast CancerStatus unknownNCT04302415
• Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast CancerStatus unknownNCT04246502Phase 2
• Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast CancerStatus unknownNCT04143906Phase 2
• Temperature and Injury in Radiotherapy Radiation Skin InjuryStatus unknownNCT04047823
• Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast CancerStatus unknownNCT03789851Not applicable
• Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection TechniqueStatus unknownNCT03541278Not applicable
• The Multi-center Validation Study of Internal Mammary Lymph Biopsy With Modified Injection Technique in Breast Cancer PatientsStatus unknownNCT03024463
• Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant RadiotherapyStatus unknownNCT02580279Phase 2
• Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast CancerStatus unknownNCT02544243Phase 2
• Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI ReconstructionStatus unknownNCT01917578Phase 3
• Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph NodeWithdrawnNCT01796444Phase 3
• Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -PositiveCompletedNCT01668914Phase 3
• Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -NegativeCompletedNCT01642511Phase 2